Granted Patent B2

US 12,746,238 · App. 18/600,097 · Granted Sep 29, 2026

Inventors: Katrina L. Jackson (Weston, MA); Christopher G. Nasveschuk (Stoneham, MA); Rhamy Zeid (Arlington, MA); Ning Yin (Lexington, MA); Gesine Kerstin Veits (Somerville, MA); Moses Moustakim (Cambridge, MA); Jeremy L. Yap (Sudbury, MA); Minsheng He (Andover, MA); Robert T. Yu (Arlington, MA); Matthew J. Schnaderbeck (Methuen, MA); Kathleen Neville (Watertown, MA); Siyi Jiang (Watertown, MA); Meiqi Li (Watertown, MA); Qianwei Liu (Watertown, MA); Manjie Zheng (Watertown, MA); Jia Li (Watertown, MA); Liwei Zhang (Watertown, MA)

Assignee: C4 THERAPEUTICS, INC.

A61K31/496A61P35/00

Abstract

Claims (24)

1 . A method for the treatment of an unresectable cancer mediated by BRD9 in a human, comprising administering to the human an effective amount of a compound of Formula:

or a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein the cancer is relapsed.

3 . The method of claim 1 , wherein the cancer is refractory.

4 . The method of claim 1 , wherein the cancer is a SMARCB1-perturbed cancer.

5 . The method of claim 1 , wherein the cancer is selected from synovial sarcoma, malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, cribriform neuroepithelial tumor, renal medullary carcinoma, epithelioid sarcoma, epithelioid malignant peripheral nerve sheath tumor, schwannomas in familial schwannomatosis, chordoma, myoepithelial carcinoma, and sinonasal carcinoma.

6 . The method of claim 1 , wherein the cancer is synovial sarcoma.

7 . The method of claim 1 , wherein the cancer is a soft tissue sarcoma.

8 . The method of claim 1 , wherein the cancer is a clear cell renal cell carcinoma.

9 . The method of claim 1 , wherein the cancer is multiple myeloma.

10 . The method of claim 1 , wherein one or more additional therapeutically active agents are administered.

11 . A method for the treatment of a cancer mediated by BRD9 in a human, comprising administering to the human an effective amount of a compound of Formula:

or a pharmaceutically acceptable salt thereof, wherein the cancer is an epithelioid malignant peripheral nerve sheath tumor, schwannomas in familial schwannomatosis, atypical malignant teratoid rhabdoid tumor, or cribriform neuroepithelial tumor.

12 . The method of claim 11 , wherein one or more additional therapeutically active agents are administered.

13 . A method for preventing the recurrence of a BRD9 mediated disorder in a human comprising administering to the human an effective amount of a compound of Formula:

or a pharmaceutically acceptable salt thereof.

14 . The method of claim 13 , wherein the BRD9 mediated disorder is a cancer.

15 . The method of claim 14 , wherein the cancer is a SMARCB1-perturbed cancer.

16 . The method of claim 14 , wherein the cancer is selected from synovial sarcoma, malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, cribriform neuroepithelial tumor, renal medullary carcinoma, epithelioid sarcoma, epithelioid malignant peripheral nerve sheath tumor, schwannomas in familial schwannomatosis, chordoma, myoepithelial carcinoma, and sinonasal carcinoma.

17 . The method of claim 14 , wherein the cancer is synovial sarcoma.

18 . The method of claim 14 , wherein the cancer is a soft tissue sarcoma.

19 . The method of claim 14 , wherein the cancer is a clear cell renal cell carcinoma.

20 . The method of claim 14 , wherein the cancer is multiple myeloma.

21 . The method of claim 14 , wherein one or more additional therapeutically active agents are administered.

Assignments (6)

Continuity (5)

References Cited (125)